EZH2 and cardiac hypertrophy: In conclusion, our study revealed that CaMKII is a new target of suppression by EZH2-mediated H3K27me3 and is epigenetically inhibited by TINCR, which will provide a novel therapeutic strategy for cardiac hypertrophy.